Myocardial Infarction News and Research

RSS

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Study reveals the detrimental effects of high concentration levels of dangerous ultrafine particles in tunnels

A toxic cocktail of ultrafine particles is lurking inside road tunnels in concentration levels so high they have the potential to harm drivers and passengers, a new study has found.

28 Aug 2009

Study reveals benefits of balloon dilation to heart patients with moderately impaired renal function

People with kidney disease undergo balloon dilation treatment after myocardial infarction less frequently, and therefore have a poorer prognosis. This according to new clinical research published in the journal Circulation.

26 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Research study concludes the difference in mortality between men and women depending on the type of ACS

A new study from NYU School of Medicine found that women may have a slightly higher risk of death than men in the thirty days following an acute coronary syndrome (ACS), but that these differences appear to be attributable to factors such as severity and type of ACS.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Women face higher risk of mortality rate following acute coronary syndromes

Women may have a slightly higher risk of death than men in the 30 days following an acute coronary syndrome (ACS; such as heart attack or unstable angina), but this difference appears attributable to factors such as severity and type of ACS, clinical differences and angiographic severity according to a study in the August 26 issue of JAMA.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Research reveals smokeless tobacco users at higher risk of a heart attack or stroke

People who use smokeless tobacco products like snus have a slightly higher risk of having a fatal heart attack or stroke, according to research published on bmj.com today.

21 Aug 2009

Study shows lower short-term mortality rates in patients hospitalized for AMI

From 1995 to 2006, hospital 30-day death rates decreased significantly for Medicare patients hospitalized for a heart attack, as did the variation in the rate between hospitals, according to a study in the August 19 issue of JAMA.

19 Aug 2009

Protein unfolding key to understanding blood clot mechanics

Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers -- a blood clot -- that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?

6 Aug 2009

Celera and Aurora to collaborate on cardiovascular genetics

Aurora Health Care, Wisconsin's largest health care provider, and Celera Corporation announced today that they have entered into an agreement to collaborate on the integration of genetic testing aimed at optimizing heart care for Aurora patients

6 Aug 2009

Emergency physicians should trust their judgment on chest pain symptoms

Their research suggests that emergency physicians should counsel with other physicians against discharge when they feel strongly about a patient for whom there is no compelling data, other than our evaluation and judgment, Chandra said.

4 Aug 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Skin disease psoriasis associated with cardiovascular disease and increased mortality

The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death, according to a report in the June issue of Archives of Dermatology.

16 Jun 2009

Fatigue common after heart attack

Half of all patients who undergo myocardial infarction (heart attack) are experiencing onerous fatigue four months after the infarction. The patients who are most fatigued are those who perceive the infarction as a sign of chronic illness, those who experience the illness as difficult to control, and those who believe that the illness has a large impact on their life. These are the conclusions of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden.

5 Jun 2009

Drug-eluting stents more effective than bare-metal stents in heart attack patients

NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.

26 May 2009

Discovery of genetic link between periodontitis and heart attack

The relationship between the dental disease periodontitis and coronary heart disease (CHD) has been known for several years. Although a genetic link seemed likely, until now its existence was uncertain. Now, for the first time, scientists have discovered a genetic relationship between the two conditions, a researcher told the annual conference of the European Society of Human Genetics today (Monday 25 May).

25 May 2009

Aspirin lowers risk of stroke in peripheral artery disease

An analysis of previous studies indicates that among patients with peripheral artery disease, aspirin use is associated with a statistically nonsignificant decrease in the risk of a group of combined cardiovascular events (nonfatal heart attack, nonfatal stroke, and cardiovascular death), but is associated with a significant reduction in the risk of one of these events, nonfatal stroke, although the findings may be limited by the lack of a large study population, according to an article in the May 13 issue of JAMA, the Journal of the American Medical Association.

12 May 2009

Myocardial Infarction News and Research

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Study reveals the detrimental effects of high concentration levels of dangerous ultrafine particles in tunnels

Study reveals benefits of balloon dilation to heart patients with moderately impaired renal function

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Research study concludes the difference in mortality between men and women depending on the type of ACS

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Women face higher risk of mortality rate following acute coronary syndromes

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Research reveals smokeless tobacco users at higher risk of a heart attack or stroke

Study shows lower short-term mortality rates in patients hospitalized for AMI

Protein unfolding key to understanding blood clot mechanics

Celera and Aurora to collaborate on cardiovascular genetics

Emergency physicians should trust their judgment on chest pain symptoms

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Skin disease psoriasis associated with cardiovascular disease and increased mortality

Fatigue common after heart attack

Drug-eluting stents more effective than bare-metal stents in heart attack patients

Discovery of genetic link between periodontitis and heart attack

Aspirin lowers risk of stroke in peripheral artery disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News